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1. Introduction 
Biosensors are widely used for health applications. Indeed, the current success of biosensors 
is attributed to the extraordinary demands of disease diagnoses and control, as well as the 
ability of biosensors to offer a convenient, hygienic, rapid, and compact method for personal 
monitoring. Biosensors offer enormous potential for detecting a wide range of analytes in 
the health care and food industries and in environmental monitoring. As quoted, 
MicroChips president John Santini expects the technology to be used as in-the-flesh 
physicians within 10 years: "It's a very exciting time," he says. "Our next step is a manually, 
wirelessly controlled biosensor that detects and treats an acute condition, and then a 
biosensor that will approximate an artificial organ; it'll sense a condition and respond 
automatically without user intervention." In this chapter, we review applications and 
advances in biosensor technology, focusing on four applications in the health field: 1) 
investigation of the interaction of antigens with antibodies produced in healthy and 
diseased subjects, 2) disease markers and virus detection, 3) clinical diagnosis and control of 
emerging infectious diseases, and 4) market potentials. Specifically, we discuss the 
application of a label-free biosensor based on ellipsometry in the development of future 
biosensors, the current and future clinical applications of this technology, and its viability. 
The goal of this chapter is to provide a brief description of the role of biosensors in in vitro 
diagnostics and scientific research related to the health field. Readers interested in 
competing or related technologies (e.g., ellipsometry, microfluidics, and surface 
modification technologies) are referred to one of several excellent recent reviews (Jin et al., 
2011; Qi et al., 2009a; Zhang, et al., 2005). In the following section, health applications are 
described using a label-free biosensor based on ellipsometry. 
2. Label-free biosensor based on ellipsometry 
2.1 Biomedical application history 
The first publication concerning biological application of antigen and antibody is a paper by 
Langmuir and Schaefer dating back to 1936 (Hans, 1998, as cited in Langmuir& Schaefer, 
1936). The interaction between an antigen-immobilized substrate and the corresponding 
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antibodies was observed with an optical technique. Although this original 'immunosensor' 
was over 59 years old at the time, the concept of a biosensor was first brought forward in 
1995 by Jin and Hans and used to study biomolecular interactions (Jin et al., 1995, 1996). A 
biomolecule layer composed of a common protein, such as fibrinogen, human serum 
albumin, or human immunoglobulin G, was spread on the surface of the sensor. The 
interaction between general proteins such as fibrinogen and an antibody against fibrinogen 
was then investigated. However, biosensor detection of clinical samples was only recently 
developed, such as detection of disease markers and viruses and investigation of 
interactions between antibodies and antigens related to clinical diagnoses (Jin et al., 2011; Qi 
et al., 2009a).  
2.2 Technical characteristics of the biosensor based on ellipsometry 
The principle of the biosensor has been discussed in several reports (Jin et al., 2011; Z.H. 
Wang et al., 2006). Here, we list some key technical characteristics of biosensors based on 
ellipsometry: 
• Label-free 
When the interaction between biomolecules occurs, the variation of the molecular mass surface 
concentration on the surface is identified by the biosensor based on ellipsometry without label 
(e.g., the horseradish peroxidase used in enzyme-linked immunosorbent assays). 
• High-throughput 
Combined with a microfluidic array reactor, which fabricates the chips, the biosensor based 
on ellipsometry has become an automatic and high-throughput system by adding ligand, 
washing, blocking, and reacting samples. Recently, an 8×6 biomolecule reactor-array was 
developed as a promising technique for a parallel protein assay. The 48 protein arrays in the 
8×6 matrix are shown in Figure 1 (Jin, 2008). Interaction of common protein, detection of five 
hepatitis B virus markers in patient serum, detection of different ladder concentrations, and 
the detection sensitivity of CD146 (known as the melanoma cell adhesion molecule or cell 
surface glycoprotein MUC18) (Guezguez B, 2007) are presented on the chip. 
• Rapid 
Using the automatic program of the microfluidic array reactor to add ligands, washing, 
blocking, and reacting samples, ligands screening and detection of markers can be 
accomplished in 1 to 2 h. 
• Low sample consumption 
Consumption of ligands and samples is on the microliter level. For example, in hepatitis B 
virus detection, hepatitis B virus ligand consumption is 10 μl/area (The area is a small 
squareness area, see Figure 1.), and hepatitis B virus serum consumption is 40 μl/area (Qi, et 
al. 2009a). Enzyme-linked immunosorbent assays in milliliter level require a larger volume 
of the same concentration.  
• Low damage to the biomolecules 
The biosensor works via an optical, reflection-based technique that uses polarized light to 
determine the optical properties of a sample (Z.H. Wang, et al., 2003a). It is almost “touch-
free” to read the detection result, so there is a decreased effect to bioactivity than, for 
instance, atomic force microscopy and surface-enhanced laser desorption/ionization. 
• High sensitivity 
The biosensor displays different detection sensitivity toward different samples. For 
example, the sensitivity of the biosensor for detecting antigen markers, such as hepatitis B 
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virus surface antigen, reaches 1 ng/ml (Qi, et al. 2009a), while the detection sensitivity of 
CD146 is < 1 ng/ml (see Figure 1: F5, F6, and F7 areas). 
 
 
Fig. 1. Forty-eight protein arrays in a matrix. Left: The visual result of a protein micro-array. 
Right: The detailed reactants relative to the left graph (Jin, 2008). 
• Automatic control  
Some parameters of the microfluidic array reactor, such as the position number of the 
sample plate, flow velocity in the microfluidic array reactor of sample or ligand, time of 
immobilization or reaction, and number of cycles, can be edited in the automatic program. 
• Visualization of results  
Visualized gray-scale images are offered by imaging ellipsometry in several seconds, which 
is shown on a computer screen. The target interacting ligands on the surface can be 
identified by values in gray-scale with associated software. 
• Quantitative detection  
Combined with the calibration curve method, disease markers and viruses in samples can 
be detected easily and quantitatively with the label-free biosensor. 
2.3 Operational process of the biosensor based on ellipsometry 
The operational process of the biosensor, which includes surface modification, ligand 
immobilization, biomolecule interaction, and result reading, is shown in Figure 2. 
Surface modification is a process by which chemical reagents for reactive groups on the 
silicone surface for biomolecule immobilization Surface modification has two obvious 
functions: one is the presentation of ligand on the biosensing surface; and the other is to 
prevent nonspecific binding (Jin, 2008). Presently, surface modification methods include 
physical adsorption, chemical covalent immobilization, and biologic modification. Physical 
adsorption is seldom used because the immobilized proteins suffer partial denaturation and 
tend to leach or wash off of the surface and compete with adsorption (Bhatia, et al., 1989). 
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Chemical covalent immobilization is often used to immobilize proteins due to the strong, 
stable linkage, and biological modification is a future direction because it provides oriented 
immobilization and better biological compatibility. Aldehyde modification, carboxyl 
modification, and biologically oriented immobilization are often used in biomedical 
applications (Qi, et al., 2010, 2009b; Z.H. Wang & Jin, 2004, 2003a). 
 
 
Fig. 2. Operational process of the biosensor based on ellipsometry. Antibodies (or antigens) 
can be immobilized as ligands to each patterned area as a bio-probe on the modified surface 
of a silicon substrate. Each bio-probe can capture its corresponding antigens (or antibodies) 
in a test sample pumped by microfluidic reactor. When the corresponding antigens (or 
antibodies) in the solution interact with the bio-probes, forming a complex, the surface 
concentration becomes higher than the initial bio-probe layer. The distribution of the lateral 
protein layer pattern is simultaneously detected by imaging ellipsometry, which may 
further point to the existence of antigens (or antibodies) in the tested solution (Jin, 2008). 
3. Applications in the health field 
In the field of human health, there is an increasing demand for inexpensive and reliable 
sensors to quickly detect and analyze various and rapidly changing disease markers. For 
example, patients frequently display rapid variations in biochemical levels of disease 
markers such as C-reactive protein that require instant assays to detect. Indeed, early 
detection and diagnosis can be used to greatly reduce the cost of patient care associated with 
the advanced stages of many diseases. More than a hundred types of proteins recognized as 
diseases markers can be detected by traditional analytical techniques such as enzyme-linked 
immunosorbent assays. However, based on the above features of the ellipsometry-based 
biosensor, it has also been widely used to detect and monitor biomolecule interactions, 
especially for biomedical applications. A sample focusing on tumor marker detection is 
shown in Figure 3.  
The ability to detect pathogenic and physiologically relevant biomolecules in the body with 
high sensitivity and specificity offers the opportunity for early diagnosis and treatment of 
diseases. 
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Fig. 3. Application of the biosensor. The use of biosensors to detect tumor markers in serum 
has spread widely (Jin, 2011). 
3.1 The interaction of antigens with antibodies in healthy and diseased subjects 
The initial impetus for advancing biosensors based on ellipsometry came from detection of 
the interaction of general antibodies and antigens, and some basic methods have been 
established, such as the ligand immobilization, high specificity probe screening, protein 
delivery, biomolecule affinity presentation on a chip, specific interactions, the influence of 
nonspecific binding, detection sensitivity, sample consumption, and calibration curves for 
quantitative detection. 
3.1.1 Detection of antigen-antibody interactions  
In biomedicine, human fibrinogen, hepatitis B surface antigen, human immuoglobulin G, 
and human serum albumin are often used as mode proteins. Using the aforementioned 
proteins as models with the biosensor, the feasibility is shown in Figure 4. Significant 
increases of gray-scale value appear in the square areas exposed to the corresponding target 
(Jin, et al., 2003). These results demonstrate that target samples can be identified by the 
ellipsometry-based biosensor. 
3.1.2 Real-time detection of the antibody-antigen interaction  
The biosensor based on ellipsometry can monitor protein interactions in situ and in real time 
to provide protein interaction kinetics information, such as association rate, dissociation 
rate, and affinity constants. Some special operation details of real-time detection are shown. 
• Model proteins were prepared and immobilized on the substrate;  
• The chip was inserted into the reaction cell; 
• A mixture of antiserum containing corresponding antibody was poured into the 
reaction cell; 
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• A series of images (in gray-scale) of several binding processes between antibodies in 
solution and antigens were recorded by the biosensor; and 
• The surface concentrations of analytes in the analytical areas of each image were 
measured and plotted versus time to determine the real-time binding curves. 
 
 
Fig. 4. Detection of several model proteins using the biosensor based on ellipsometry. Model 
proteins Fib, AntiHBsA, IgG and HSA were immobilized in four different columns, 
respectively. Phosphate-buffered saline was added to one area as a reference control. 
Corresponding target was then added to the other two areas in the column. (Z.H. Wang & 
Jin, 2003b) 
 
 
Fig. 5. Binding curves of anti-fibrinogen/fibrinogen (■), anti-human 
immunoglobulin/human immunoglobulin (●), and anti-human serum albumin/human 
serum albumin (▲) obtained by the biosensor (Z.H. Wang & Jin, 2003b). 
The real-time binding curves are shown in Figure 5. Detailed data processing and kinetics 
analysis was performed according to the method described in the literature (Malmborg, et 
al., 1992). In a clinical setting, a patient’s serum is a mixture similar to that used to generate 
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Figure 5, containing antibodies against fibrinogen, human serum albumin, and human 
immunoglobulin. A chip contains many immobilized ligands that bind to the same marker 
in serum but with different binding affinities. The biosensor offers a convenient way to 
compare these ligands’ binding affinities under the same conditions, and ligands with high 
affinity can be screened. The convenient way comparing these ligands’ binding affinities 
might compare the effectiveness of drug and screen drug, so the ability to sense multiple 
interactions in real-time makes the biosensor particularly well suited for monitoring disease 
progress, screening for highly effective drugs, and understanding disease mechanisms. 
The interaction of antigens and antibodies produced in healthy and diseased subjects (e.g., 
hepatitis B markers antibodies and antigens (Qi, et al., 2009a), severe acute respiratory 
syndrome virus particles and antibodies (Qi, et al., 2006a), ricin antibody screening (ricin 
found in castor beans is one of the most potent plant toxins) (Niu, et al., 2010), and others) 
has been studied by the biosensor based on ellipsometry. These studies demonstrate the 
biosensor’s use for health applications. 
3.2 Disease markers and virus detection 
Protein markers should be specific and sensitive and have prognostic value. Efforts to 
discover disease markers have focused on elucidating serum molecules that have diagnostic 
and prognostic value (Schena, 2005). High-throughput biosensors, including the biosensor 
based on ellipsometry, may shorten the time required to find disease markers. In this 
respect, biosensors are the best choice among the current techniques. 
3.2.1 Qualitative detection of five hepatitis B virus markers 
Hepatitis B virus is a human hepadnavirus that causes acute and chronic hepatitis and 
hepatocellular carcinoma (Bai, et al., 2003). The detection of hepatitis B virus markers is 
clinically important for the diagnosis of infection with this virus (Chen, et al., 2006). Five 
markers of hepatitis B virus (including hepatitis B surface antigen, the hepatitis B surface 
antibody, hepatitis B e antigen, hepatitis B e antibody, and hepatitis B core antibody) are a 
group of general markers used in the monitoring of hepatitis B virus infection. Following 
key steps of detection markers were operated for clinical application:  
• Screening for highly effective probes; 
• Detection sensitivity; and 
• Optimization of detection conditions. 
Presently, several probes can be simultaneously compared by the biosensor on one chip, 
which is shown in Figure 6. For the same target, different probes present different values in 
the grayscale, which indicates that the various probes have different bioactivities. Thus, 
highly effective probes were found for sensitive clinical diagnosis.  
Sensitivity is important for hepatitis B marker detection. Hepatitis B surface antibody and 
hepatitis B surface antigen national positive reference samples (from the National Institute 
for the Control of Pharmaceutical and Biological Products (China)) were detected by the 
biosensor in 2009. The detection sensitivity of hepatitis B surface antigen is 1 ng/ml, and the 
detection sensitivity of hepatitis B surface antibody is > 1 IU/ml. Thus, the sensitivity has 
already reached clinical standards.  
The biosensor based on ellipsometry permits multiplexed analysis. It can detect the five 
Hepatitis B markers of several patients simultaneously in about 1 h, proving its feasibility in 
clinical diagnosis. High affective probes increase sensitivity and resolving power. Other 
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biosensor advantages, such as higher sensitivity, a simplified process, and short test time, 
are also significant for rapid diagnosis.  
 
 
Fig. 6. Screening of hepatitis B ligands. (a) Screening of hepatitis B surface antibody and 
hepatitis B surface antigen. Different lots of hepatitis B surface antibody (sAb) and antigen 
(sAg) ligands were first immobilized in different rows. After blocking with BSA, the first 
row was used as a control. Different lots of hepatitis B surface antigen and hepatitis B 
surface antibody markers were detected in different rows. (b) Screening for hepatitis B e 
antibody and hepatitis B e antigen. The italics indicate results with the largest variation in 
gray-scale values, which in turn indicate that the ligands had higher bioactivity (Qi, et al., 
2009a). 
3.2.2 Quantitative detection of breast cancer marker: Carbohydrate antigen 15-3  
In 2008, an estimated 636,000 cases of breast cancer were diagnosed in high resource 
countries, while an additional 514,000 cases were diagnosed in low and middle resource 
countries, where it has now become the most common female cancer (El Saghir, et al., 2011). 
Carbohydrate antigen 15-3 is frequently measured as a breast cancer marker test using the 
biosensor based on ellipsometry (Zhang, et al., 2005). According to Figure 2, quantitative 
analysis of carbohydrate antigen 15-3 was performed using the calibration curve method:  
• A serum sample with a known concentration of carbohydrate antigen 15-3 was serially 
diluted; 
• These various concentrations were detected; 
• A calibration curve was drawn using the 15-3 concentration as the abscissa and the 
gray-scale value as the vertical axis; 
• An unknown sample was analyzed; and 
• The concentration of 15-3 in the unknown sample was determined with the calibration 
curve. 
The concentration of carbohydrate antigen 15-3 in a serum sample had been determined by 
an electrochemiluminescence immunoassay. The serum sample with known concentration is 
used as standard sample to make a calibration curve of the biosensor. The calibration curve 
of carbohydrate antigen 15-3 detection is shown in Figure 7. The index period of the curve is 
0~20 kIU/L, corresponding to gray-scale values of 58~99. If the concentration exceed the 
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detection scope (0~20 kIU/L), the unknown test samples must be diluted; the lower limit of 
detection is 1 kIU/L. The realization of quantitative label-free detection of a cancer marker 
may aid in earlier diagnosis, monitoring the course of the disease, even exploring the 
mechanism of cancer. 
 
 
Fig. 7. Calibration curve for carbohydrate antigen 15-3 concentration detection (Zhang, et al., 
2005). 
3.2.3 Detection of tumor markers 
Analyzing only one tumor marker is insufficient to diagnose cancer in 2010, a review 
exhibited a novel co-detection of three common tumor markers: alpha-fetoprotein, alpha-L-
fucosidase, and ferritin (Jin, 2011). Thus, quantitative analysis was performed by the 
biosensor with the following calibration curve method: 
• A chip was designed to simultaneously detect three markers in a sample;  
• A calibration curve for the biosensor was plotted;  
• A cut off value was determined by the receiver operating characteristic; and 
• The three markers in a clinical serum sample were examined on a chip. 
Detection results of several patients’ markers were compared and analyzed. Sensitivity 
reached the ng/ml or U/L level. Thirty-two normal sera and 24 liver cancer patient sera 
were quantitatively analyzed. The realization of simultaneous detection of several markers 
by the biosensor may increase diagnostic specificity in a clinical setting. 
3.2.4 Detection of phage M13KO7 for building virus a detection model  
Phages are estimated to be the most widely distributed and diverse entities in all reservoirs 
populated by bacterial hosts. In 2009, Phage M13KO7 was detected by the biosensor based 
on ellipsometry as a model for virus detection. A highly versatile and powerful virus 
detection platform has been established (Qi, et al., 2009b). Based on common 
antibody/antigen or disease marker detection, three key steps (e.g., ligand immobilization, 
sensitivity detection, and microscopic confirmation) were optimized.  
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The avidin/biotin method (Fig. 8) was chosen to immobilize the antibody bio-GP3 against 
phage M13KO7. The avidin/biotin immobilization method is often used in other 
immunoassays (Vijayendran & Leckband, 2001). It has several advantages: 1) ligands are 
strongly immobilized because biotin and avidin can specifically interact with stronger 
affinity (~1015M−1) than the antibody-antigen interaction (~105-1012M−1) (Friguet, et al., 1985; 
Malmborg, et al., 1992); 2) immobilization is oriented, which helps antibody display its Fab 
domain for improved sensitivity; and 3) it may offer a more physiological environment.  
 
 
Fig. 8. Avidin/biotin immobilization method (Vijayendran & Leckband, 2001). 
The sensitivity of phage M13KO7 detection can reach 109 plaque forming units/ml. Phage 
detection results by the biosensor have been confirmed with atomic force microscope. 
Imaging indicates that the biosensor can capture whole viruses, not just fragments. Thus, the 
virus detection biosensor platform has potential applications for human health.  
3.2.5 Detection of avian influenza virus 
According to World Health Organization statistics, the number of cases of avian influenza 
virus H5N1 directly crossing barriers and infecting humans was 534, causing 316 deaths by 
March 2011 (World Health Organization, 2011). Avian influenza virus subtype H5 can be 
detected with the biosensor based on ellipsometry using the above virus detection platform.  
The oriented immobilization of probe was realized using protein A and antibody for avian 
influenza virus detection. Figure 9 (A) shows the probe immobilization method. This is a 
kind of biological immobilization, which also offers a more physiologically relevant 
environment to maintain the bioactivity of the probe (Qi, et al., 2010). The results show that 
4A4 antibody can react specifically with avian influenza virus subtype H5N1, while CAM4 
can interact with both H5N1 and H9N2. 
The sensitivity of H5N1 detection is 2.56×10−3 tissue culture infectious dose/ml, which is 
more sensitive than a lateral-flow immunoassay (Remel Inc.). The corresponding areas were 
scanned with near-field optical microscopy. The microscopic evidence is presented in Figure 
10, showing that intact avian influenza virus particles were bound. Direct virus detection 
may help with earlier diagnosis than disease marker detection. 
3.2.6 Detection of other disease markers and viruses  
C-reactive protein (Zhu, et al., 2007), soluble angiopoietin receptor Tie-2 (C.L. Wang, et al., 
2009), thymidine phosphorylase (Li, et al., 2004), Alzheimer's disease tau protein (Qi, et al., 
2006b), and others had also been detected using the biosensor. These diseases markers are 
closely related to human health. Thus, qualitative or quantitative detection with the 
biosensor can aid in earlier disease diagnosis and improve health. 
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Fig. 9. Detection of avian influenza virus samples using the biosensor based on ellipsometry. 
(A) Schematic illustration. Avian influenza virus antibody is immobilized on the substrate. 
(B) Experimental image in gray-scale and a 3-D gray-scale distribution map. Antibody 
CAM4 was immobilized in columns ‘a’ and ‘b’; 4A4 in columns ‘c’ and ‘d’; H5N1, H9N2 and 
the control are shown in rows ‘1’, ‘2’, and ‘3’, respectively (Qi, et al., 2010). 
 
 
Fig. 10. Near-field optical microscopy images of H5N1. (A) and (B) Shear force mode images 
for H9N2 and H5N1, respectively. (C) Reflection mode image of H5N1. (D) 3-D reflection 
mode image of H5N1 (Qi, et al., 2010). 
3.3 Clinical diagnosis and control of emerging infectious diseases 
The ability of the biosensor based on ellipsometry to detect antibodies or antigens, disease 
markers, and viruses from patient samples with high sensitivity and specificity offers a 
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powerful opportunity in early diagnosis and treatment of diseases. Related clinical 
applications have begun. 
3.3.1 Clinical diagnosis of hepatitis B patients’ sera 
Hepatitis B virus infection is the most common cause of chronic liver diseases; an estimated 
350 million people are chronically infected with hepatitis B virus worldwide (Sun, et al., 
2002). Further, hepatitis B virus infection plays an important role in the development of 
hepatocellular carcinoma (De Mitri, et al., 2010). A rapid, simple, and direct method is 
urgently needed for clinical hepatitis B diagnosis. In section 3.2.1, the screening probe, 
standard national reference sample detection, and highly sensitive hepatitis B detection 
results demonstrated that the biosensor based on ellipsometry is feasible for clinical 
diagnosis of the disease (Z.H. Wang, et al., 2006; Jin, et al., 2004). Thus, the application of the 
biosensor based on ellipsometry could greatly enhance hepatitis B detection speed. 
Cut-off values are important for clinical diagnosis of hepatitis B and it detection by the 
biosensor based on ellipsometry. The cut-off value can help us to distinguish between strong 
positive, near cut-off, and negative samples. Other diagnosis techniques, such as enzyme-
linked immunosorbent assays, have cut-off value instructions included in the assay kits (Qi, 
et al., 2009a). The cut-off value of the biosensor was determined with a receiver operating 
characteristic curve. With the cut-off value, the detection of five hepatitis B virus markers by 
the biosensor was consistent with enzyme-linked immunosorbent assays.  
Sera from 169 patients were analyzed with the biosensor for the purpose of clinical 
diagnosis. Samples from 60 patients included clinical information of hepatitis B from 
Shandong Provincial Hospital from qualitative enzyme-linked immunosorbent assay 
detection results (the assay kit was produced by Shanghai Rongsheng Biotech Co. Ltd). The 
remaining samples were from patients from the Tientsin Blood Disease Hospital and also 
included clinical information of hepatitis B (the assay kit was produced by Beijing Wantai 
Co Ltd.) Figure 11 shows the detection results of 109 hepatitis B patients’ sera samples from 
 
 
Fig. 11. Comparison of hepatitis B surface antigen detection by the biosensor based on 
ellipsometry (■) and by enzyme-linked immunosorbent assays (△) (Qi, et al., 2009a).  
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the Tientsin Blood Disease Hospital. The hepatitis B surface antigen detection results using 
the biosensor are compared with those of enzyme-linked immunosorbent assays. Regression 
analysis revealed that the results are in good agreement between the two methods 
(r=0.67>r0.01=0.247). 
The biosensor based on ellipsometry allows the multiplexed analysis and detection of five 
hepatitis B virus markers in clinical samples. The biosensor has a simplified process and 
short test time, which can detect the five markers from several patients simultaneously in 
about 1 h. The higher throughput of the biosensor may enable improved setup for detection 
sensitivity, time, and accuracy in the future.  
3.3.2 Quantitative detection of clinical sera from breast cancer patients  
Breast cancer incidence rates vary widely across the world, from 19.3 per 100,000 women 
per year in Eastern Africa to 89.9 per 100,000 women per year in Western Europe (Ferlay, et 
al., 2010). Carbohydrate antigen 15-3 is particularly valuable for treatment monitoring in 
patients that have breast cancer that cannot be evaluated using existing radiological 
procedures. Carbohydrate antigen 15-3 is also used during the postoperative surveillance of 
asymptomatic women who have undergone surgery for invasive breast cancer.  
Using the quantitative calibration curve in section 3.2.2, 60 clinical patients’ serum samples 
were quantitatively analyzed with the biosensor, including 24 women with intraductal 
carcinoma, 15 with mucinous carcinoma, 5 with in situ lobular carcinoma, 2 with medullary 
carcinoma, and 14 with breast diseases but no evidence of cancer (Zhang, et al., 2005). Thirty 
healthy sera were also collected. The median patient age was 48.5 years. These clinical sera 
samples were examined with both the biosensor based on ellipsometry and 
electrochemiluminescence immunoassays (Elecsys 2010 system, Roche Diagnostics) via the 
double-blinded method. The electrochemiluminescence immunoassay is the gold standard 
of breast cancer marker carbohydrate antigen 15-3 detection. A receiver operating 
characteristic plot curve  (Handley, et al., 1982) was used to determine the result of the 
biosensor based on ellipsometry, which is shown in Figure 12.  
 
 
Fig. 12. Receiver operating characteristic curve analysis of the data from the biosensor based 
on ellipsometry and electrochemiluminescence immunoassays (Zhang, et al., 2005). 
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The result of this analysis proved that the biosensor results are consistent with those of the 
electrochemiluminescence immunoassay, reaching the clinical diagnosis standard level. 
3.3.3 Clinical detection of sera from severe acute respiratory syndrome coronavirus 
(SARS-CoV)-infected patients  
The outbreak of SARS in late 2002 in southeast China spread rapidly to over 30 countries 
and resulted in more than 800 deaths (Poutanen, et al., 2003; Feng & Gao, 2007). In 2003, the 
biosensor based on ellipsometry was used to detect the infectious pathogens.  
Before analyzing clinical SARS patients’ sera, some antibodies from a phage-display library 
were identified by the biosensor. SARS-CoV virions were used as a probe by the biosensor 
to assess the efficiency of the antibodies b1 and h12. The identification of new and effective 
antibodies is significant for more accurate diagnosis of the illness and the development of a 
vaccine. 
Ten SARS patients and 12 healthy volunteers (controls) were tested with the biosensor. 
SARS-CoV virions were immobilized on the surface as the probe to detect antibodies in the 
patients’ sera (Figure 13). From the analysis of the results, different patients had different 
antibody contents, which might help doctors estimate disease progress. The entire detection 
process only requires approximately 40 min.  
 
 
Fig. 13. Analysis of SARS patients’ serum samples using the biosensor based on imaging 
ellipsometry. a1~12 are negative samples; b1~12 are SARS patients; and c1~12 are blank 
controls (Qi, et al., 2005). 
The real-time function of the biosensor was mentioned above in section 3.1.2. The kinetic 
process of interaction between the antibodies and SARS virus was analyzed with the 
biosensor. The affinity of antibodies b1 and h12 for SARS virus are 9.5×106 M−1 and 1.36×107 
M−1, respectively. Real-time detection revealed that antibody h12 has a higher affinity for the 
virus than antibody b1.  
As a label free method, the biosensor based on ellipsometry is a competent mechanism for 
analyzing clinical serum samples from SARS patients and the affinity between these 
antibodies and the SARS coronavirus. Compared with surface plasmon resonance (SPR), a 
fairly widely applied optical detection method for real-time detect interaction of 
biomolecules (Hall, et al., 2010), the biosensor also allows label-free samples and crude 
samples to be used directly without previous purification. The biosensor based on 
ellipsometry has advantages such as: 1) lower cost (e.g., a piece of the biosensor based on 
ellipsometry silicon wafer is about $1, while a piece of surface plasmon resonance glass slide 
costs about $70-80); 2) the biosensor can provide 24 real-time curves simultaneously, 
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allowing high-throughput detection; and 3) multiplex microarray was imaged and offered 
an image. 
3.4 Market potential for scientific research related to the health field 
The continual development of the biosensor based on ellipsometry shows both market 
potential for scientific research related to the health field and an increasing number of 
applications for basic biology research. The following are two applications of the biosensor 
on vesicular membrane proteins, demonstrating its value to general biology. 
3.4.1 Detection of interaction among vesicular membrane fusion proteins 
Membrane-associated proteins provide the minimal fusion machinery necessary for cellular 
vesicles to fuse to target organelle membranes in eukaryotic cells (Jahn & Scheller, 2006). 
The qualitative and quantitative identification of membrane-associated proteins interactions 
is the key to understanding the mechanisms of membrane fusion, which is vital for cell 
division, cellular structure organization, and biological information processing (Zhang, et 
al., 2009). To investigate the characteristics of these newly discovered membrane-associated 
protein pairs such as: Sec22, Ykt6, Sso2 and Sso1, the biosensor based on ellipsometry was 
used to detect the interactions among soluble N-ethylmaleimide-sensitive factor attachment 
protein receptors (SNAREs, a kind of protein that assembles into coiled-coil tetramers to 
promote membrane fusion). The interactions among several SNAREs (i.e., Sec22, Ykt6, Sso1, 
and Sso2) were analyzed by the biosensor based on ellipsometry. The in vitro detection 
results from the biosensor are consistent with the results of yeast two-hybrid assays at the 
domain level in vivo (Zhang, et al., 2009; Jin et al., 2011). Further, the kinetic binding process 
of two SNAREs (Ykt6 and Sso2) was measured using the real-time function of the biosensor. 
The rapid detection and identification of vesicular protein–protein interactions is essential 
for understanding vesicle trafficking and for understanding the system-level organization of 
cellular structure, biological information processing, and molecular mechanisms. 
3.4.2 Vesicle adsorption visualization 
Recently, a type of total internal reflection imaging ellipsometry was developed for real-time 
detection of biomolecular interactions (Jin, et al., 2011). This method was used to 
visualization the of vesicles adsorption process. Non-specific adsorption and desorption on 
a poly-L-lysine-modified gold surface was analyzed with real-time curves by the biosensor. 
The biosensor results were consistent with a phase contrast microscopy (NIKON, TI-U, 
Japan) results. The vesicle adsorption and desorption processes visualized by the biosensor 
are significant to the study of cell membrane properties. Micron target detection is the future 
aim of the biosensor based on total internal reflection imaging ellipsometry. Therefore, we 
expect that the biosensor based on ellipsometry has a yet-unexploited huge market potential 
for application in biological basic research related to the health field. 
4. Summary 
In the human health field, the biosensor based on ellipsometry is widely used to monitor or 
detect biological molecules for applications ranging from common infectious diseases to 
cancers. Some adaptations of this system for biomedical and clinical applications (e.g., 
disease marker detection, virus detection, and real-time monitoring) have been developed. 
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With recent progress on vesicular membrane proteins, the biosensor based on ellipsometry 
technology also shows significant promise in basic biological research. Furthermore, 
through miniaturization, it is possible to fabricate the biosensors that are portable, low-cost, 
high-throughput, and highly sensitive for diseases such as HIV/AIDS. As the biosensor 
based on ellipsometry becomes simpler and more widely available, we expect to see a 
proliferation of uses in conjunction with telecommunications equipment. Wide application 
of the biosensor based on ellipsometry will be explored in monitoring personal health, the 
food we consume, and our environment in the future. 
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